Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab

Journal article


Publication Details

Author(s): Weide B, Martens A, Hassel JC, Berking C, Postow MA, Bisschop K, Simeone E, Mangana J, Schilling B, Di Giacomo AM, Brenner N, Kaehler K, Heinzerling L, Gutzmer R, Bender A, Gebhardt C, Romano E, Meier F, Martus P, Maio M, Blank C, Schadendorf D, Dummer R, Ascierto PA, Hospers G, Garbe C, Wolchok JD
Journal: Clinical Cancer Research
Publication year: 2016
Volume: 22
Journal issue: 22
Pages range: 5487-5496
ISSN: 1078-0432


Abstract

PURPOSE: Biomarkers for outcome after immune-checkpoint blockade are strongly needed as these may influence individual treatment selection or sequence. We aimed to identify baseline factors associated with overall survival (OS) after pembrolizumab treatment in melanoma patients.
EXPERIMENTAL DESIGN: Serum lactate dehydrogenase (LDH), routine blood count parameters, and clinical characteristics were investigated in 616 patients. Endpoints were OS and best overall response following pembrolizumab treatment. Kaplan-Meier analysis and Cox regression were applied for survival analysis.
RESULTS: Relative eosinophil count (REC) ≥1.5%, relative lymphocyte count (RLC) ≥17.5%, ≤2.5-fold elevation of LDH, and the absence of metastasis other than soft-tissue/lung were associated with favorable OS in the discovery (n = 177) and the confirmation (n = 182) cohort and had independent positive impact (all P < 0.001). Their independent role was subsequently confirmed in the validation cohort (n = 257; all P < 0.01). The number of favorable factors was strongly associated with prognosis. One-year OS probabilities of 83.9% versus 14.7% and response rates of 58.3% versus 3.3% were observed in patients with four of four compared to those with none of four favorable baseline factors present, respectively.
CONCLUSIONS: High REC and RLC, low LDH, and absence of metastasis other than soft-tissue/lung are independent baseline characteristics associated with favorable OS of patients with melanoma treated with pembrolizumab. Presence of four favorable factors in combination identifies a subgroup with excellent prognosis. In contrast, patients with no favorable factors present have a poor prognosis, despite pembrolizumab, and additional treatment advances are still needed. A potential predictive impact needs to be further investigated. Clin Cancer Res; 22(22); 5487-96. ©2016 AACR.


FAU Authors / FAU Editors

Heinzerling, Lucie Prof. Dr.
Hautklinik


External institutions with authors

Deutsches Krebsforschungszentrum (DKFZ)
Eberhard Karls Universität Tübingen
Institut Curie
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
Medizinische Hochschule Hannover (MHH) / Hannover Medical School
Memorial Sloan Kettering Cancer Center
Netherlands Cancer Institute (NKI)
Università degli Studi di Siena (UNISI) / University of Siena
Universitätsklinikum Gießen und Marburg (UKGM)
Universitätsklinikum Heidelberg
Universitätsklinikum Köln
Universitätsklinikum Schleswig-Holstein (UKSH)
Universitätsklinikum Tübingen
Universität Zürich (UZH)
University of Groningen / Rijksuniversiteit Groningen


How to cite

APA:
Weide, B., Martens, A., Hassel, J.C., Berking, C., Postow, M.A., Bisschop, K.,... Wolchok, J.D. (2016). Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab. Clinical Cancer Research, 22(22), 5487-5496. https://dx.doi.org/10.1158/1078-0432.CCR-16-0127

MLA:
Weide, Benjamin, et al. "Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab." Clinical Cancer Research 22.22 (2016): 5487-5496.

BibTeX: 

Last updated on 2018-14-11 at 09:08